癌相关抗原125在恶性卵巢肿瘤治疗前后的变化

目的 对卵巢癌相关抗原125（CA125）在恶性卵巢肿瘤治疗前后进行不同时间段的动态监测，并探讨其临床应用价值。方法 采用电化学发光免疫分析法测定恶性卵巢肿瘤患者不同时间段的血清（或血浆）CA125值，观测其在恶性卵巢肿瘤患者治疗前后的变化。结果 在恶性卵巢肿瘤患者治疗中，术前及术后等5个不同时间段CA125的检测结果显示，术前与术后有明显差异，测定结果的均值由术前的197．2U／ml降低为术后1年的24．8U／ml；术前数据范围为10～1129U／ml、检出阳性率80．7％，术后1年数据范围降低为7．0～79．9U／ml、检出阳性率19．2％。结论 CA125的动态监测在恶性卵巢肿瘤患者治疗中有较好的临床应用价值。

Change of tumor marker CA125 in patients with malignant ovarian neoplasm before and after treatment

Objective To investigate the clinical value of tumor marker CA125 by dynamic detecting CA125 of patients with malignant ovarian neoplasm before and after treatment.Methods Serum or plasma CA125 level of patient with malignant ovarian neoplasm was detected by electrochemoluminescence immunoassay at different time-points.Results The levels of CA125 of patients with malignant ovarian neoplasm was significantly different before and after operation.The mean level dropped down from 197.2 U/ml(10-1 129 U/ml) before operation to 24.5 U/ml(7.0-79.9 U/ml) one year after operation.And the positive rate dropped down from 80.7% to 19.2%.Conclusion The dynamic detecton of CA125 has important clinical value in the treatment of patients with malignant ovarian neoplasm.